Drugs / Botensilimab
Trials 39 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07128355 | May 2026 → Jan 2027 expected | metastasis from malignant tumor of colon | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07193862 | Dec 2025 → Apr 2028 expected | colorectal cancer | Northwell Health | Recruiting | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT07695311 | Oct 2026 → Oct 2029 expected | Ewing sarcoma, desmoplastic small round cell tumor | Rabi Hanna | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06411691 | Jun 2025 → Mar 2028 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06336902 | Jan 2025 → Jan 2027 expected | colorectal adenocarcinoma | University of Southern California | Recruiting | No outcome recorded |
| Phase 1 | NCT06076837 | Jan → Dec 2025 | pancreatic adenocarcinoma | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 1 | NCT06095674 | Jan 2024 → Jan 2026 | cervical cancer | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 1 | NCT05377528 | Jul 2022 → Dec 2024 | neoplasm | Agenus Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04121676 | Sep 2019 → Feb 2024 | cancer of unknown primary site | Agenus Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03860272 | Mar 2019 → Jan 2025 overdue | angiosarcoma, cancer of unknown primary site, colorectal cancer, endometrial cancer +4 | Agenus Inc. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05672316 | May 2023 → May 2025 overdue | colorectal adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05627635 | May 2023 → Jun 2026 overdue | colon adenocarcinoma, rectum adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07595874 | Dec 2026 → May 2027 expected | colon adenocarcinoma, rectum adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07516366 | Aug 2026 → Aug 2027 expected | clear cell renal carcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07551596 | Aug → Sep 2026 expected | colorectal adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07578337 | Jul 2026 → Feb 2029 expected | pancreatic neoplasm | Nelum Corp | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07550088 | Jun 2026 → Sep 2028 expected | colorectal cancer | Scripps Health | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227636 | Nov 2025 → Nov 2030 expected | rectal carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06843551 | Jun 2025 → Aug 2030 expected | pancreatic ductal adenocarcinoma | Benjamin Spieler | Recruiting | No outcome recorded |
| Phase 2 | NCT06780787 | May 2025 → Nov 2027 expected | rectum adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06843434 | Feb 2025 → Feb 2028 expected | rectum adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06589440 | Nov 2024 → Sep 2027 expected | colorectal cancer | Stingray Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT06268015 | Nov 2024 → Jul 2028 expected | colorectal cancer | Nicholas DeVito, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06575725 | Nov 2024 → Jan 2027 | colon adenocarcinoma, rectum adenocarcinoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05632328 | Aug 2024 → Aug 2026 overdue | pancreatic ductal adenocarcinoma | Bruno Bockorny | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06322108 | Jun 2024 → Apr 2030 expected | non-small cell lung carcinoma | Immune Oncology Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06300463 | Mar 2024 → Dec 2026 expected | metastasis from malignant tumor of colon | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 2 | NCT06251973 | Feb 2024 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05864534 | Jan 2024 → Jul 2031 expected | IDH-wildtype glioblastoma, gliosarcoma | Northwestern University | Recruiting | No outcome recorded |
| Phase 2 | NCT05928806 | Sep 2023 → Nov 2026 | renal cell carcinoma | Michael B. Atkins, MD | Suspended | No outcome recorded |
| Phase 2 | NCT05845450 | May 2023 → May 2026 overdue | colorectal carcinoma | Gruppo Oncologico del Nord-Ovest | Recruiting | No outcome recorded |
| Phase 2 | NCT05630183 | Mar 2023 → Jan 2026 | pancreatic ductal adenocarcinoma | Agenus Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05571293 | Mar 2023 → Nov 2024 overdue | colorectal neoplasm | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05529316 | Dec 2022 → Feb 2028 expected | melanoma | Agenus Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05608044 | Nov 2022 → Sep 2027 expected | colorectal cancer | Agenus Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04028063 | Jan 2020 → Apr 2027 expected | soft tissue sarcoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06279130 | Jan 2024 → Jan 2029 expected | — | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07152821 | Mar → Jul 2026 | colorectal cancer | Canadian Cancer Trials Group | Terminated | No outcome recorded |
| Phase 3 | NCT06346197 | Dec 2025 → May 2028 expected | gastric cancer, metastatic malignant neoplasm | Centre Leon Berard | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06751524 Background | — | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm, melanoma +4 | Agenus Inc. | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botensilimab | “Botensilimab, an Fc-enhanced anti-CTLA-4 antibody (FcE-aCTLA-4), has shown durable activity in "cold" and immunotherapy-refractory cancers.” PMID 39028616 ↗ Nov 202439“SR-8541A administered orally in combination with intravenous botensilimab and balstilimab” NCT06589440 ↗ “Anti-CTLA-4 antibody botensilimab” NCT06095674 ↗ |
| Known as | AGEN-1181 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650435 ↗ |
| Action | Inhibit | “Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic...” PMID 38871975 ↗ Jun 2024 |
| Modality | Monoclonal antibody | “An Fc-engineered anti-CTLA-4 monoclonal antibody” NCT03860272 ↗ |
| Route | Intravenous | “AGEN2373 and botensilimab administered by IV.” NCT04121676 ↗ |
| Target | CTLA4 | “Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody” NCT04028063 ↗ |